Join leading experts from industry, research, clinics, policy and innovation ecosystems for two days dedicated to the future of radiopharmaceutical innovation.
Hosted in one of Europe’s fastest-growing radiopharmaceutical regions, the Radiopharmacy Forum Dresden 2026 brings together stakeholders from across the entire value chain to discuss innovation, isotope supply, clinical translation, infrastructure, regulation and patient access.
The event is organized in close connection with the growing nukliD® ecosystem and highlights Dresden and Central Germany as an emerging hub for radiopharmaceutical innovation and production.
Date
Time
until 08.10.2026, 2:00 PM
Location
Expected Audience
Language
Organizer
PROGRAM
Agenda
Two days, four main topics and numerous opportunities for professional exchange. The agenda covers current developments in radiopharmacy, theranostics, clinical translation, regulation and international value chains.
11:00 – 12:30
Registration & Welcome Lunch
12:30 – 13:00
Opening
Sebastian M. Schmidt (Helmholtz-Zentrum Dresden-Rossendorf)
Staatssekretär Sebastian Scheel (Sächsisches Staatsministerium für Wirtschaft, Arbeit, Energie und Klimaschutz)
Peggy Jungke (nukliD Clustermanagement)
13:00 – 14:00
Session I
Isotope Supply & Production
Setting the Scene Can Europe secure its isotope supply? Gunnar Mann (EZAG)
European Radioisotopes Valley Initiative Georgi Simeonov (European Commission)
Production and Processing of 99Mo-Based Radiodiagnostics Without Fissile Material Using Accelerator-Driven Neutron Sources Thomas Gutberlet (FZJ)
DANTE - Fusion for versatile Isotope production Volker Naulin (DANTE Fusion)
Theranext – Accelerator-Based Isotope Production & BNCT Sebastian Nowak (Theraneutronics Technologies)
StandardX: Building an Isotope Refinery Mark Bray-Parry (StandardX)
14:00 – 14:45
Networking Break
14:45 – 15:45
Session II
Radiopharmaceutical Innovation
Setting the Scene Which innovations will define the next generation of radiotheranostics? Klaus Kopka (Helmholtz-Zentrum Dresden-Rossendorf)
Outlook on the development of radioligand therapy at Novartis Sandra Schmidt (Novartis Pharma)
Advances in Pb-212 Based Radiopharmaceuticals Michael Schultz (Perspective Therapeutics)
The Trivehexin / Therahexin Theranostic Pair: Breakthrough in αvβ6-Integrin Targeted Radioligand Therapy Johannes Notni (TRIMT)
Monocyte Activation Test (MAT) for Radiopharmaceuticals Marco Nousch (CUP Laboratorien Dr. Freitag GmbH )
15:45 – 16:30
Networking Break
16:30 – 17:30
Session III
ClinicalTranslation & Infrastructure
Setting the Scene Why does translation still take so long? Ralph Bundschuh (Universitätsklinikum Carl Gustav Carus Dresden)
High-contrast PET imaging of urothelial carcinoma and triple-negative breast cancer using Nectin-4-directed radiolabelled bicyclic peptides Robert Wodtke (Helmholtz-Zentrum Dresden-Rossendorf)
OreBridge Therapeutics – Accelerating Translation from Discovery to First-in-Human ThuHang Lai (ROTOP Pharmaka)
New Stars on the Horizon? – Clinical Implementation of Fancy Nuclides like Tb-161 Max Kranick (Medizinische Universität Lausitz – Carl Thiem)
TBA tbc Moira Kent (Synexa Life Sciences)
17:30 – 17:45
Quick Break
17:50 – 18:50
Session IV
Policy & Market Access
Setting the Scene What does Germany need to remain globally competitive? Stefan Knupfer (AOK PLUS)
Healthcare & Market Access Perspective Julia Lämmel (AOK PLUS)
Technological Sovereignty – Supply Chains & Technological Capacities Torsten Bathmann (Verband forschender Arzneimittelhersteller e.V.)
From Molecule to Market – Regulatory Challenges Along the Radiopharmaceutical Value Chain Rene Martin (ABX)
Ensuring Patient Access: Nuclear Medicine's Role in the GeSiG Debate and the Competence Network's Policy Engagement Jana Bernhold (Pathways Public Health GmbH)
19:00 – 20:15
Radiopharma Connect Dinner
20:15- 20:45
Leadership Dialogue
powered by Wirtschaftsförderung Sachsen
Building Europe's Next Radiopharma Hub
Andreas Lippert (Wirtschaftsförderung Sachsen)
Robert Breitner (Landeshauptstadt Dresden)
Dominic Eberle (Sächsisches Staatsministerium für Wirtschaft, Arbeit, Energie und Klimaschutz)
Alexandra Skorupa (Novartis)
Torsten Bathmann (Verband Forschender Arzneimittelhersteller e.V.)
Sponsors
Why participate?
01
End-to-End Ecosystem
02
Strategic Networking
03
Future Opportunities
Where and how to get there?
LÖWENSAAL Dresden
Dr.-Külz-Ring 10 | 01067 Dresden
Directions by train: From Dresden Central Station, it’s a 10- to 15-minute walk through the “Prager Straße” pedestrian zone directly to our building.
Getting here by public transit: The “ Prager Straße,” served by lines 3, 4, 7, 11, 12, 62, 68, 333, and 360. Additionally, Dresden’s central stop, “Postplatz,” is about a 5-minute walk from our building.
Arriving by car: Please use the parking garages in the immediate vicinity of our building, e.g.,
- Centrum Galerie, entrance at Reitbahnstraße 8
- Altmarkt Galerie, Webergasse 1
- Galeria Dresden, Prager Straße 12
- Stadtforum underground parking garage, Waisenhausstraße 14
And the parking spots:
- Budapester Straße parking lot
- Waisenhausstraße parking lane
Any questions?
Your contact person
Dr. Peggy Jungke
Clustermanagement nukliD®
Online Registration CLOSED
Registration is now closed as the maximum number of participants has been reached.
If you are still interested in attending the Radiopharmacy Forum Dresden 2026, you are welcome to submit your details via the registration form or contact us directly. Should places become available due to cancellations, we may be able to offer them at short notice.




